MRNA on XNAS, Health Care, Moderna, Inc., job postings
Measures activity, not value. Not investment advice.
Shares up 772% in a year while the company lost $2.8B and insiders sold $50.8M.
BadFree cash flow ran at minus $2B over 12 months
GoodNew institutional positions rose to 317, 5.9 times a year earlier
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.3B, net income $162.0M.
31 Dec 2021RevenueNet incomeNet losstallest bar $7.2B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$1.3B
$162.0M
30 Jun 2026
$145.0M
-$782.0M
31 Mar 2026
$389.0M
-$1.3B
31 Dec 2025
$678.0M
-$826.0M
30 Sep 2025
$1.0B
-$200.0M
30 Jun 2025
$142.0M
-$825.0M
31 Mar 2025
$108.0M
-$971.0M
31 Dec 2024
$966.0M
-$1.1B
30 Sep 2024
$1.9B
$13.0M
30 Jun 2024
$241.0M
-$1.3B
31 Mar 2024
$167.0M
-$1.2B
31 Dec 2023
$2.8B
$217.0M
30 Sep 2023
$1.8B
-$3.6B
30 Jun 2023
$344.0M
-$1.4B
31 Mar 2023
$1.9B
$79.0M
31 Dec 2022
$5.1B
$1.5B
30 Sep 2022
$3.4B
$1.0B
30 Jun 2022
$4.7B
$2.2B
31 Mar 2022
$6.1B
$3.7B
31 Dec 2021
$7.2B
$4.9B
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$2.5B
$2.2B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+13%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$2.8B
-$3.1B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$7.10
-$8.07
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
28.0%
48.3%
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-116%
-155%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-110%
-140%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-34.5%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$2.0B
-$2.7B
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$5.2B
$4.5B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$3.5B
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$1.6B (net cash)
-$4.5B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.52
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$16.90
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
31.2
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
30.6
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
11.5
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$50.8M
bought $0, sold $50.8M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+35%
1,029 13F filers vs 763
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
77%
310.7M shares held by 13F filers (30 Sep 2026) of 404.6M outstanding (30 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
8.2%
33.2M shares sold short (30 Oct 2026) of 404.6M outstanding (30 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.8
33.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+1.8%
32.6M shares sold short in the report before, 33.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
51%
51% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
241
Tracked since 21 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 21 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+29%
$1.3B vs $1.0B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+42%
$47.0M vs $33.0M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$1.4M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
92
92 articles in the last 7 days; its usual week has 10.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
8.8×
92 articles in the last 7 days; its usual week has 10.5.
Unusual now sharp changes in the last 90 days, compared with its own past
New institutional positions 317, 5.9× a year earlier
Page views 18K, 11× a year earlier
Price $195.00 on 20 Nov 2026, +772% over 12 months (12-month range $22.36 to $269.00)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $98.5M in the last 12 months (the 12 months before: $5.8M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, +150% on the 12 months before.Revenue per quarter. Revenue $1.3B in the latest quarter, +29% on a year earlier.Capital spending per quarter. Capital spending $47.0M in the latest quarter, +42% on a year earlier.Institutional holders (13F filers). 1,029 13F filers reported holding it in the latest 13F quarter, +72% on a year earlier.Lobbying spend. Lobbying spend: $1.4M published in the last 12 months, +48% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $7.2B; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $6.1B, +213% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $4.7B, +9.1% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $3.4B, -32% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $5.1B, -29% on a year earlier; public on 25 Feb 2023
Quarter ended 31 Mar 2023: $1.9B, -69% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $344.0M, -93% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $1.8B, -46% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $2.8B, -45% on a year earlier; public on 24 Feb 2024
Quarter ended 31 Mar 2024: $167.0M, -91% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $241.0M, -30% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $1.9B, +1.7% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $966.0M, -66% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $108.0M, -35% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $142.0M, -41% on a year earlier; public on 2 Aug 2025
Quarter ended 30 Sep 2025: $1.0B, -45% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $678.0M, -30% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $389.0M, +260% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $145.0M, +2.1% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $1.3B, +29% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $132.0M, +277% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $87.0M; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $89.0M, -10% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Mar 2023: $113.0M, -14% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $234.0M, +169% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $140.0M, +57% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $220.0M; public on 24 Feb 2024
Quarter ended 31 Mar 2024: $196.0M, +73% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $182.0M, -22% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $151.0M, +7.9% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $522.0M, +137% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $117.0M, -40% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $3.0M, -98% on a year earlier; public on 2 Aug 2025
Quarter ended 30 Sep 2025: $33.0M, -78% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $39.0M, -93% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $62.0M, -47% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $37.0M, +1133% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $47.0M, +42% on a year earlier; public on 7 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 971; public on 14 Feb 2022
31 Mar 2022 report: 926; public on 16 May 2022
30 Jun 2022 report: 907; public on 15 Aug 2022
30 Sep 2022 report: 822; public on 14 Nov 2022
31 Dec 2022 report: 967; public on 14 Feb 2023
31 Mar 2023 report: 929; public on 15 May 2023
30 Jun 2023 report: 871; public on 14 Aug 2023
30 Sep 2023 report: 804; public on 14 Nov 2023
31 Dec 2023 report: 802; public on 14 Feb 2024
31 Mar 2024 report: 842; public on 15 May 2024
30 Jun 2024 report: 887; public on 14 Aug 2024
30 Sep 2024 report: 728; public on 14 Nov 2024
31 Dec 2024 report: 693; public on 14 Feb 2025
31 Mar 2025 report: 658; public on 15 May 2025
30 Jun 2025 report: 634; public on 14 Aug 2025
30 Sep 2025 report: 600; public on 14 Nov 2025
31 Dec 2025 report: 646; public on 17 Feb 2026
31 Mar 2026 report: 698; public on 15 May 2026
30 Jun 2026 report: 763; public on 14 Aug 2026
30 Sep 2026 report: 1,029; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $130K published
Quarter from 1 Apr 2022: $175K published
Quarter from 1 Jul 2022: $175K published
Quarter from 1 Oct 2022: $165K published
Quarter from 1 Jan 2023: $175K published
Quarter from 1 Apr 2023: $175K published
Quarter from 1 Jul 2023: $175K published
Quarter from 1 Oct 2023: $175K published
Quarter from 1 Jan 2024: $155K published
Quarter from 1 Apr 2024: $195K published
Quarter from 1 Jul 2024: $80K published
Quarter from 1 Oct 2024: $90K published
Quarter from 1 Jan 2025: $170K published
Quarter from 1 Apr 2025: $200K published
Quarter from 1 Jul 2025: $320K published
Quarter from 1 Oct 2025: $280K published
Quarter from 1 Jan 2026: $280K published
Quarter from 1 Apr 2026: $370K published
Quarter from 1 Jul 2026: $490K published
Quarter from 1 Oct 2026: $300K published
What is unusual now
Made public in the last 90 days: it saw 317 13F filers open a new position in the quarter ended 30 Sep 2026, 5.9× the same quarter last year; it also drew 18K Wikipedia page views in the week of 17 Aug 2026, 11× the same week last year.
Many funds opening a new position: saw 317 13F filers open a new position in the quarter ended 30 Sep 2026, 5.9× the same quarter last year Public on 16 Nov 2026.
Wikipedia attention spike: drew 18K Wikipedia page views in the week of 17 Aug 2026, 11× the same week last year Public on 25 Aug 2026.
In 12 months: 4 major agreements, 3 director or officer changes. Results releases and routine reports are left out.
Filed
What happened
Source
16 Nov 2026
Amended credit agreement with Ares Capital as agent: reduced interest margins by 0.75 points; maturity extended to Nov 24, 2031Same filing: took on new debt
241 open postings; careers site tracked since 21 Nov 2026. Most in Research & science 13%, Test, quality & reliability 10%, Manufacturing & production 7%, Operations & administration 5%.
Reported lobbying spend: $300K in Q3 2026, $490K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
5 Mar 2025
New
Holland & Knight LLPfor Moderna, Inc.
Tax Reform - Restoring the Orphan Drug Tax Credit.Taxation
Two or more unrelated kinds of records unusual within 30 days
25 Feb 2025confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Moderna(MRNA): had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year, while it spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year. Two unrelated kinds of activity within 35 days.
Short interest and volume: Short interest spike, became public on 28 Jan 2025
Short interest and volume: Short interest spike, became public on 12 Feb 2025
Financials: Quarterly capital spending jump, became public on 25 Feb 2025
Short interest and volume: Short interest spike, became public on 27 Feb 2025
The 15 Jan 2025 report against the 24 reports before it.
this reportearliernormal: 22.9MSee the evidence (4 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2025
Moderna had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year.
This period
43.0M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
22.9M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+6.9
Same report last year
23.1M
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 22.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Feb 2025
Moderna had 40.6M shares sold short in the 31 Jan 2025 report, 1.9× the same report last year.
This period
40.6M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
23.4M
Typical spread (median absolute deviation)
2.4M
How far from its usual level
+4.9
Same report last year
20.9M
History used
2,590 days
the 31 Jan 2025 report24 earlier reportsnormal: 23.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 25 Feb 2025
Moderna spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year.
This period
$522.0M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$166.5M
Typical spread (median absolute deviation)
$41.5M
How far from its usual level
+5.8
Same quarter last year
$220.0M
History used
2,467 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $166.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 27 Feb 2025
Moderna had 42.3M shares sold short in the 14 Feb 2025 report, 1.8× the same report last year.
This period
42.3M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
24.5M
Typical spread (median absolute deviation)
3.3M
How far from its usual level
+3.6
Same report last year
24.1M
History used
2,604 days
the 14 Feb 2025 report24 earlier reportsnormal: 24.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
10 Oct 2023confirmed
Confirmed across sources Attention and Filings + Financials
Moderna(MRNA): drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year, while it spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year. Two unrelated kinds of activity on the same day.
Attention: Wikipedia attention spike, became public on 10 Oct 2023
Financials: Quarterly capital spending jump, became public on 10 Oct 2023
The week of 2 Oct 2023 against the 26 weeks before it.
this weekearliernormal: 3,116See the evidence (2 changes)
Attention: Wikipedia attention spike became public on 10 Oct 2023
Moderna drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year.
This period
6,486 (the week of 2 Oct 2023)
Normal week (median of 26 earlier)
3,116
Typical spread (median absolute deviation)
216
How far from its usual level
+10.5
Same week last year
3,702
History used
1,741 days
the week of 2 Oct 202326 earlier weeksnormal: 3,116
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Financials: Quarterly capital spending jump became public on 10 Oct 2023
Moderna spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year.
This period
$234.0M (the quarter ended 30 Jun 2023)
Normal quarter (median of 7 earlier)
$89.0M
Typical spread (median absolute deviation)
$24.0M
How far from its usual level
+4.1
Same quarter last year
$87.0M
History used
1,917 days
the quarter ended 30 Jun 20237 earlier quartersnormal: $89.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
24 Nov 2020confirmed
Confirmed across sources Attention and Filings + Financials
Moderna(MRNA): reported revenue of $157.9M for the quarter ended 30 Sep 2020, 9.3× the same quarter last year, while it drew 269K Wikipedia page views in the week of 16 Nov 2020, 722× the same week last year. Two unrelated kinds of activity within 21 days.
Financials: Quarterly revenue change, became public on 3 Nov 2020
Attention: Wikipedia attention spike, became public on 24 Nov 2020
The quarter ended 30 Sep 2020 against the 8 quarters before it.
this quarterearliernormal: $16.5MSee the evidence (2 changes)
Financials: Quarterly revenue change became public on 3 Nov 2020
Moderna reported revenue of $157.9M for the quarter ended 30 Sep 2020, 9.3× the same quarter last year.
This period
$157.9M (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
$16.5M
Typical spread (median absolute deviation)
$5.8M
How far from its usual level
+16.4
Same quarter last year
$17.0M
History used
1,279 days
the quarter ended 30 Sep 20208 earlier quartersnormal: $16.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Attention: Wikipedia attention spike became public on 24 Nov 2020
Moderna drew 269K Wikipedia page views in the week of 16 Nov 2020, 722× the same week last year.
This period
269K (the week of 16 Nov 2020)
Normal week (median of 26 earlier)
11K
Typical spread (median absolute deviation)
4,325
How far from its usual level
+40.2
Same week last year
372
History used
691 days
the week of 16 Nov 202026 earlier weeksnormal: 11K
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
16 Nov 2026Institutional holdings change
saw 317 13F filers open a new position in the quarter ended 30 Sep 2026, 5.9× the same quarter last year.
Same quarter last year: 54; its normal quarter is 72.5.
See the evidence
This period
317 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
72.5
Typical spread (median absolute deviation)
11.5
How far from its usual level
+14.3
Same quarter last year
54
History used
2,830 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 72.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
drew 18K Wikipedia page views in the week of 17 Aug 2026, 11× the same week last year.
Same week last year: 1,580; its normal week is 1,337.
See the evidence
This period
18K (the week of 17 Aug 2026)
Normal week (median of 26 earlier)
1,337
Typical spread (median absolute deviation)
137
How far from its usual level
+80.9
Same week last year
1,580
History used
2,791 days
the week of 17 Aug 202626 earlier weeksnormal: 1,337
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
had 42.3M shares sold short in the 14 Feb 2025 report, 1.8× the same report last year.
Same report last year: 24.1M; its normal report is 24.5M.
See the evidence
This period
42.3M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
24.5M
Typical spread (median absolute deviation)
3.3M
How far from its usual level
+3.6
Same report last year
24.1M
History used
2,604 days
the 14 Feb 2025 report24 earlier reportsnormal: 24.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year, while it spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year. Two unrelated kinds of activity within 35 days.
See the evidence (4 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2025
Moderna had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year.
This period
43.0M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
22.9M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+6.9
Same report last year
23.1M
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 22.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Feb 2025
Moderna had 40.6M shares sold short in the 31 Jan 2025 report, 1.9× the same report last year.
This period
40.6M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
23.4M
Typical spread (median absolute deviation)
2.4M
How far from its usual level
+4.9
Same report last year
20.9M
History used
2,590 days
the 31 Jan 2025 report24 earlier reportsnormal: 23.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 25 Feb 2025
Moderna spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year.
This period
$522.0M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$166.5M
Typical spread (median absolute deviation)
$41.5M
How far from its usual level
+5.8
Same quarter last year
$220.0M
History used
2,467 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $166.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 27 Feb 2025
Moderna had 42.3M shares sold short in the 14 Feb 2025 report, 1.8× the same report last year.
This period
42.3M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
24.5M
Typical spread (median absolute deviation)
3.3M
How far from its usual level
+3.6
Same report last year
24.1M
History used
2,604 days
the 14 Feb 2025 report24 earlier reportsnormal: 24.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
25 Feb 2025Financials change
spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year.
Same quarter last year: $220.0M; its normal quarter is $166.5M.
See the evidence
This period
$522.0M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$166.5M
Typical spread (median absolute deviation)
$41.5M
How far from its usual level
+5.8
Same quarter last year
$220.0M
History used
2,467 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $166.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 40.6M shares sold short in the 31 Jan 2025 report, 1.9× the same report last year.
Same report last year: 20.9M; its normal report is 23.4M.
See the evidence
This period
40.6M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
23.4M
Typical spread (median absolute deviation)
2.4M
How far from its usual level
+4.9
Same report last year
20.9M
History used
2,590 days
the 31 Jan 2025 report24 earlier reportsnormal: 23.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year.
Same report last year: 23.1M; its normal report is 22.9M.
See the evidence
This period
43.0M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
22.9M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+6.9
Same report last year
23.1M
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 22.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 37.8M shares sold short in the 31 Dec 2024 report, 1.6× the same report last year.
Same report last year: 24.2M; its normal report is 22.9M.
See the evidence
This period
37.8M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
22.9M
Typical spread (median absolute deviation)
1.9M
How far from its usual level
+5.4
Same report last year
24.2M
History used
2,559 days
the 31 Dec 2024 report24 earlier reportsnormal: 22.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 39.5M shares sold short in the 13 Dec 2024 report, 1.8× the same report last year.
Same report last year: 21.9M; its normal report is 22.7M.
See the evidence
This period
39.5M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
22.7M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+7.3
Same report last year
21.9M
History used
2,541 days
the 13 Dec 2024 report24 earlier reportsnormal: 22.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 40.8M shares sold short in the 29 Nov 2024 report, 1.9× the same report last year.
Same report last year: 22.0M; its normal report is 22.4M.
See the evidence
This period
40.8M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
22.4M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+8.2
Same report last year
22.0M
History used
2,527 days
the 29 Nov 2024 report24 earlier reportsnormal: 22.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 39.9M shares sold short in the 15 Nov 2024 report, 1.8× the same report last year.
Same report last year: 22.4M; its normal report is 22.3M.
See the evidence
This period
39.9M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
22.3M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+7.9
Same report last year
22.4M
History used
2,513 days
the 15 Nov 2024 report24 earlier reportsnormal: 22.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 34.4M shares sold short in the 31 Oct 2024 report, 1.8× the same report last year.
Same report last year: 19.6M; its normal report is 22.2M.
See the evidence
This period
34.4M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
22.2M
Typical spread (median absolute deviation)
997K
How far from its usual level
+5.5
Same report last year
19.6M
History used
2,498 days
the 31 Oct 2024 report24 earlier reportsnormal: 22.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 33.3M shares sold short in the 15 Oct 2024 report, 1.8× the same report last year.
Same report last year: 18.1M; its normal report is 22.1M.
See the evidence
This period
33.3M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
22.1M
Typical spread (median absolute deviation)
997K
How far from its usual level
+5.0
Same report last year
18.1M
History used
2,482 days
the 15 Oct 2024 report24 earlier reportsnormal: 22.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 31.3M shares sold short in the 30 Sep 2024 report, 1.7× the same report last year.
Same report last year: 18.5M; its normal report is 22.0M.
See the evidence
This period
31.3M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
22.0M
Typical spread (median absolute deviation)
997K
How far from its usual level
+4.2
Same report last year
18.5M
History used
2,467 days
the 30 Sep 2024 report24 earlier reportsnormal: 22.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year, while it spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year. Two unrelated kinds of activity on the same day.
See the evidence (2 changes)
Attention: Wikipedia attention spike became public on 10 Oct 2023
Moderna drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year.
This period
6,486 (the week of 2 Oct 2023)
Normal week (median of 26 earlier)
3,116
Typical spread (median absolute deviation)
216
How far from its usual level
+10.5
Same week last year
3,702
History used
1,741 days
the week of 2 Oct 202326 earlier weeksnormal: 3,116
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Financials: Quarterly capital spending jump became public on 10 Oct 2023
Moderna spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year.
This period
$234.0M (the quarter ended 30 Jun 2023)
Normal quarter (median of 7 earlier)
$89.0M
Typical spread (median absolute deviation)
$24.0M
How far from its usual level
+4.1
Same quarter last year
$87.0M
History used
1,917 days
the quarter ended 30 Jun 20237 earlier quartersnormal: $89.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
10 Oct 2023Financials change
spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year.
Same quarter last year: $87.0M; its normal quarter is $89.0M.
See the evidence
This period
$234.0M (the quarter ended 30 Jun 2023)
Normal quarter (median of 7 earlier)
$89.0M
Typical spread (median absolute deviation)
$24.0M
How far from its usual level
+4.1
Same quarter last year
$87.0M
History used
1,917 days
the quarter ended 30 Jun 20237 earlier quartersnormal: $89.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year.
Same week last year: 3,702; its normal week is 3,116.
See the evidence
This period
6,486 (the week of 2 Oct 2023)
Normal week (median of 26 earlier)
3,116
Typical spread (median absolute deviation)
216
How far from its usual level
+10.5
Same week last year
3,702
History used
1,741 days
the week of 2 Oct 202326 earlier weeksnormal: 3,116
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
reported revenue of $344.0M for the quarter ended 30 Jun 2023, 93% below the same quarter last year.
Same quarter last year: $4.7B; its normal quarter is $4.9B.
See the evidence
This period
$344.0M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$4.9B
Typical spread (median absolute deviation)
$856.0M
How far from its usual level
-3.6
Same quarter last year
$4.7B
History used
2,282 days
the quarter ended 30 Jun 20238 earlier quartersnormal: $4.9B
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 95 entries; narrow the window or the kind of data to see older ones.
Not listed: 925 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001682852
Ticker
MRNA
Domain
modernatx.com
Employer name
Moderna, Inc., moderna services, Moderna US, Inc. (3 unverified)
Hq location
MA|CAMBRIDGE|02142 (1 unverified)
Lobbying client
moderna, moderna us, stanton park group llc on behalf of modernatx
Name
Moderna Australia Pty Ltd, Moderna Biopharma Canada Corporation, Moderna Biotech Distributor UK Ltd, Moderna Biotech Manufacturing UK Ltd and 27 more
Uei
LCY4PQS5SV44
Wikidata
Q17081612
Wikipedia
Moderna
DOL H-1B labor condition applications and PERM certifications235 data points16 Dec 2019 to 10 Aug 2026
Federal lobbying disclosures (LDA)10 records, 89 data points30 Jun 2019 to 30 Sep 2026
SEC Form 13F institutional holdings2 records, 288 data points31 Dec 2018 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)118 records24 Aug 2016 to 16 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)653 data points31 Dec 2015 to 30 Oct 2026
SEC Form 4 insider transactions833 records, 1996 data points18 Sep 2019 to 18 Nov 2026
FINRA short interest (twice monthly)611 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4000 data points7 Dec 2018 to 20 Nov 2026
Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026